4//SEC Filing
Orexigen Therapeutics, Inc. 4
Accession 0001181431-14-006112
CIK 0001382911operating
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 7:32 AM ET
Size
7.1 KB
Accession
0001181431-14-006112
Insider Transaction Report
Form 4
Booth Mark D
Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2014-02-07+205,000→ 205,000 totalExercise: $6.30Exp: 2024-02-06→ Common Stock (205,000 underlying) - Award
Common Stock
2013-11-29$5.34/sh+3,810$20,345→ 3,810 total
Footnotes (3)
- [F1]These shares were acquired under the Company's Employee Stock Purchase Plan.
- [F2]1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/7/2014, so that all of the shares of the stock subject to the option shall be vested on 2/7/2018, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
- [F3]Not applicable.
Documents
Issuer
Orexigen Therapeutics, Inc.
CIK 0001382911
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001382911
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 7:32 AM ET
- Size
- 7.1 KB